Gene therapy and genetic engineering are transforming the landscape of personalized and regenerative medicine by offering precise, targeted corrections at the genetic level. These technologies enable the replacement, repair, or regulation of defective genes using viral or non-viral delivery systems, significantly altering the course of inherited and acquired diseases. In tissue engineering, gene editing plays a pivotal role in programming stem cells, enhancing scaffold-cell interactions, and boosting tissue regeneration. Breakthroughs such as CRISPR-Cas9, base editing, and prime editing allow high-fidelity genomic modifications, minimizing off-target effects and increasing clinical feasibility. Gene therapy and genetic engineering are also being integrated into smart biomaterial systems and synthetic biology platforms to provide controlled release and spatially defined gene expression. As regulatory frameworks adapt, more gene-modified cell and tissue products are entering early-stage trials, suggesting a shift toward curative and adaptive solutions for complex diseases.
Title : The era of artificial intelligence (AI) and its use in regenerative medicine
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cells for human disease modelling and potential for tissue repair
Patrizia Ferretti, UCL Great Ormond Street Institute of Child Health, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : The role of gingival fibroblasts in periodontal diseases and regeneration
Katarzyna Gawron, Medical University of Silesia in Katowice, Poland
Title : Personalized and Precision Medicine (PPM): A unique healthcare model via pathology-related modelling and bi-odesign-inspired translational applications for the next gen-eration of human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation